| S.C. delivery of ultra-high concentration (up to 500 mg/mL) protein microparticle suspensions: pharmacokinetics, efficacy, biodistribution, and immunogenicity |
Sadiqua Shadbar, Lisa Liu, Yi Tang, et al. |
2025 |
Drug Delivery and Translational Research |
THA-0001
|
| A Generic Detection Method for the Doping Control Analysis of Fc-Fusion Proteins and Monoclonal Antibodies in Equine Plasma |
Cheung, H. W., Wong, S., Choi, C., et al. |
2025 |
Drug Testing and Analysis |
THP-0050
|
| A Generic Detection Method for the Doping Control Analysis of Fc-Fusion Proteins and Monoclonal Antibodies in Equine Plasma |
Cheung, H. W., Wong, S., Choi, C., et al. |
2025 |
Drug Testing and Analysis |
THP-0065
|
| A Generic Detection Method for the Doping Control Analysis of Fc-Fusion Proteins and Monoclonal Antibodies in Equine Plasma |
Cheung, H. W., Wong, S., Choi, C., et al. |
2025 |
Drug Testing and Analysis |
THP-0085
|
| A long-lasting prolactin stimulates galactopoiesis in mice |
Kready, Kasia et al. |
2025 |
iScience |
THP-0108
|
| A Generic Detection Method for the Doping Control Analysis of Fc-Fusion Proteins and Monoclonal Antibodies in Equine Plasma |
Cheung, H. W., Wong, S., Choi, C., et al. |
2025 |
Drug Testing and Analysis |
THP-0093
|
| A Generic Detection Method for the Doping Control Analysis of Fc-Fusion Proteins and Monoclonal Antibodies in Equine Plasma |
Cheung, H. W., Wong, S., Choi, C., et al. |
2025 |
Drug Testing and Analysis |
THP-0098
|
| Angiopoietin-2 binds to FGFR2, inhibits FGF-FGFR2 signaling, and delays cutaneous wound healing by inhibiting wound angiogenesis |
Minji Sim, Hidetaka Ohnuki, Stewart Durell, et al. |
2025 |
Angiogenesis |
THP-0292
|
| A Generic Detection Method for the Doping Control Analysis of Fc-Fusion Proteins and Monoclonal Antibodies in Equine Plasma |
Cheung, H. W., Wong, S., Choi, C., et al. |
2025 |
Drug Testing and Analysis |
THP-0319
|
| Activated αβ T and reduced mucosa-associated invariant T cells in LGI1- and CASPR2-encephalitis |
Daniela Esser , Louisa Müller-Miny , Michael Heming, et al. |
2025 |
Brain |
THP-0319
|
| Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control |
Sakellariou, P., Walpurgis, K., Thomas, A., et al. |
2025 |
Scientific Reports |
THP-0398
|
| A Generic Detection Method for the Doping Control Analysis of Fc-Fusion Proteins and Monoclonal Antibodies in Equine Plasma |
Cheung, H. W., Wong, S., Choi, C., et al. |
2025 |
Drug Testing and Analysis |
THP-1104
|
| A Comparative Review on the Production of Factor VIII in Human and Non-human Hosts |
Amirhossein Ghaemi, Hamid Moghimi and Mohammad-Hossein Sarrafzadeh |
2024 |
Current Pharmaceutical Design |
THP-0098
|
| A Comparative Review on the Production of Factor VIII in Human and Non-human Hosts |
Amirhossein Ghaemi, Hamid Moghimi and Mohammad-Hossein Sarrafzadeh |
2024 |
Current Pharmaceutical Design |
THP-0092
|
| A Comparative Review on the Production of Factor VIII in Human and Non-human Hosts |
Amirhossein Ghaemi, Hamid Moghimi and Mohammad-Hossein Sarrafzadeh |
2024 |
Current Pharmaceutical Design |
THP-0093
|
| A Comparative Review on the Production of Factor VIII in Human and Non-human Hosts |
Amirhossein Ghaemi, Hamid Moghimi and Mohammad-Hossein Sarrafzadeh |
2024 |
Current Pharmaceutical Design |
THP-0051
|
| A Comparative Review on the Production of Factor VIII in Human and Non-human Hosts |
Amirhossein Ghaemi, Hamid Moghimi and Mohammad-Hossein Sarrafzadeh |
2024 |
Current Pharmaceutical Design |
THP-0052
|
| Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome) |
Gusarova, V.D., Smolov, M.A., Lyagoskin, I.V. et al. |
2023 |
BioDrugs |
THP-0178
|
| Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy |
Nunez, Daniel et al. |
2023 |
Molecular Therapy Methods & Clinical Development |
THP-0108
|
| Unveiling the autoreactome: Proteome-wide immunological fingerprints reveal the promise of plasma cell depleting therapynveiling the autoreactome: Proteome-wide immunological fingerprints reveal the promise of plasma cell depleting therapy |
Bodansky A, Yu DJ, Rallistan A,et al. |
2023 |
medRxiv |
THP-0108
|
| Analysis of Botulinum Toxin A and Interacting Proteins in Skeletal Muscle Cells: An Investigation into the Mechanisms behind Botulinum Toxin A as a Treatment for Chronic Exertional Compartment Syndrome |
Kee, Lauren |
2022 |
Honors Program Projects |
THP-0027
|
| iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II |
Hong, J., Cheng, Y., Yang, S.,et al. |
2022 |
Experimental Cell Research |
THP-0178
|
| Generation of a Universal Human Complement Source by Large-Scale Depletion of IgG and IgM from Pooled Human Plasma |
Frances Alexander, Emily Brunt, Holly Humphries,et al. |
2021 |
Bacterial Vaccines |
THP-0082
|
| Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins |
Nguyen, N. H., Glassman, F. Y., Dingman, R. K.,et al. |
2021 |
Scientific Reports |
THP-0146
|
| Detection of Sotatercept (ACE-011) in human serum by SAR-PAGE and western single blotting |
Reichel, C., Farmer, L., Gmeiner, G.,et al. |
2017 |
Drug Testing and Analysis |
THP-0319
|
| Antibody-based strategies for the detection of Luspatercept (ACE-536) in human serum |
Reichel, C., Gmeiner, G., & Thevis, M. |
2017 |
Drug Testing and Analysis |
THP-0319
|
| Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of Western blotting and LC-HRMS |
Walpurgis, K., Thomas, A., Vogel, M.,et al. |
2016 |
Drug Testing and Analysis |
THP-0319
|
| Contributions of thrombin targets to tissue factor‐dependent metastasis in hyperthrombotic mice |
Yokota, N., Zarpellon, A., Chakrabarty, S.,et al. |
2014 |
Journal of Thrombosis and Haemostasis |
THP-0212
|
